OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
The article OpenAI acquires Orchestra Bio to build AI agents that speed up drug development appeared first on The Decoder.
This article has been indexed from The Decoder
Read the original article: